NCT07154953Not yet recruiting
Serum Surfactant Protein-D as Predictor of Disease Severity in Hospitalized COPD Patients
Serum Surfactant Protein-D and Inflammatory Biomarkers as Predictors of Disease Severity in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients
Source: ClinicalTrials.gov · Last updated 10 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
evaluation of the serum levels of surfactant protein-D (SP-D), C-reactive protein (CRP), fibrinogen, and peripheral blood neutrophilic and eosinophilic counts in patients with COPD correlation of these biomarkers with clinical, functional, and radiological parameters
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 27 Aug 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Assiut University
- Diseases
- COPD
- NCT number
- NCT07154953
What you commit to
- Study type: Observational
- Planned participants: 75
- From 1 Dec 2025 to the primary completion date, 1 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active pulmonary infection unrelated to COPD (e.g. tuberculosis, fungal infections)
- Other chronic lung diseases such as asthma, interstitial lung disease, or lung cancer
- Use of systemic corticosteroids for conditions other than COPD exacerbation
Who the study is looking for
- Adults ≥40 years diagnosed with COPD based on prior diagnosis or spirometry if available.
- Admission for acute exacerbation (AECOPD) in ward or Respiratory ICU.
Age in the registry: 40 years to 88 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.